ORLANDO, Fla., May 14, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB) announced today that it will be presenting at the 4th Annual Immuno-Oncology: BD&L and Investment Forum on Friday, June 1 at 3:40PM CDT (the time may be subject to changes depending on the conference organizers) at the Waldorf Astoria Chicago Hotel in Chicago, Illinois. Hemispherx is a research and development company focused on unmet medical needs in immunology, with a special emphasis in immuno-oncology. It is also an emerging commercial development company, based upon commercial approvals of Alferon® in the United States and Argentina for refractory or recurring external genital warts and Argentina for patients who become refractory to or intolerant to recombinant alpha interferon, as well as regulatory approval of Ampligen® in Argentina for severe Chronic Fatigue Syndrome (CFS).
David R. Strayer, M.D., Chief Scientific & Medical Officer of Hemispherx, will be presenting and meeting with investors one-on-one. Dr. Strayer’s presentation will focus on immuno-oncology, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), and immune system amplification for enhanced viral vaccines. Dr. Strayer will also discuss the successfully completed production of a commercial size batch of vials of Ampligen® for expanded clinical programs and commercial sales as well as other milestones.
Hemispherx has two flagship products: Alferon N Injection® approved in the United States and Argentina, and Ampligen® approved in Argentina with a NDA pending in the United States. The Company also has six orphan drug designations, with four in the United States and two in the European Union. Ampligen® has the potential to address multiple indications, including various cancers, ME/CFS and influenza. Alferon N Injection® also has multiple potential indications, including MERS and as a component of an immune modulating cocktail designed to favorably improved the microenvironment of several solid tumors. Their combined estimated market is estimated in the billions of dollars.
About 4th Annual Immuno-Oncology: BD&L and Investment Forum
Taking place on the first day of ASCO, the 4th Annual Immuno-Oncology: BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. 250 delegates and about 30 presentations by listed and private biotechnology companies seeking licensing & investment are expected. To learn more about the 4th Annual Immuno-Oncology: BD&L and Investment Forum, please click this link.
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for the treatment of seriously debilitating disorders. Hemispherx's flagship products include the FDA-approved drug Alferon N Injection® and the Argentina-approved drug rintatolimod (tradenames Ampligen® or Rintamod®). Rintatolimod is a double-stranded RNA being developed for globally important debilitating diseases and disorders of the immune system, including Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Hemispherx's platform technology includes components for the potential treatment of various severely debilitating and life-threatening diseases. Because rintatolimod has not been designated safe and effective by the FDA for general use, it is legally available in the United States only through clinical trials, however, Ampligen® has been approved in Argentina for ME/CFS and the company is working toward legal access in other countries where early access programs exist for serious diseases, such as ME/CFS, with unmet medical needs. Ampligen® is the only therapy approved anywhere in the world for ME/CFS. An Ampligen® EAP approval has also been obtained for therapeutic use in the Netherlands for pancreatic cancer.
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.hemispherx.net. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.
Phone Number: 800-778-4042